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Obesity, lipoprotein subclass concentrations and insulin resistance are predictors 
of cardiovascular disease (CVD). The Lamin A/C (LMNA) C1908T polymorphism has 
been associated with obesity-related anthropometric and biochemical traits, higher fasting 
triglyceride, lower HDL-cholesterol concentrations and the metabolic syndrome. Aerobic 
exercise training has been shown to generate favorable changes in body composition, 
lipoprotein-lipid profile and insulin sensitivity and to reduce CVD risk. The purpose of 
this project was to examine the effect of the C1908T polymorphism on percent body fat, 
plasma lipoprotein-lipid profile and insulin sensitivity in sedentary subjects before, and 
their change with, 24 weeks of exercise training. Following IRB approval, 144 sedentary 
adults underwent dietary stabilization, body composition scans, a 3-hour oral glucose 
tolerance test (OGTT) and plasma lipoprotein-lipid profile analysis. Genotyping was 
performed using standard techniques. Following baseline testing, 104 subjects completed 
six months of aerobic exercise training and then underwent a final body composition 
scan, 3-hour OGTT and plasma lipoprotein-lipid profile analysis. Comparisons were 
made between C-allele carriers and TT homozygotes; ANOVA and ANCOVA 
procedures were utilized to examine the effects of the C1908T polymorphism on percent 
body fat, lipoprotein-lipid profile and insulin sensitivity before, and their changes with, 
24-weeks of aerobic exercise training. Statistical significance was set at p0.05 level. 
Overall, genotype frequencies were as predicted by Hardy-Weinberg equilibrium. There 
were no significant differences between the genotype groups regarding body 
composition, lipoprotein-lipid profile or OGTT variables at baseline, nor were there 
significant differences in the change with exercise training of these variables between the 
two genotype groups. This study suggests that components of the metabolic syndrome 
and certain CVD risk factors may not be dependent on LMNA A/C genotype. However, a 
larger and more balanced study population across genotype groups may be needed to 
reach a definitive conclusion.
THE EFFECTS OF LAMIN A/C C1908T POLYMORPHISM ON BODY 
COMPOSITION, PLASMA LIPOPROTEIN-LIPID PROFILE AND INSULIN 
SENSITIVITY CHANGES WITH EXERCISE TRAINING
by
Faith Melissa Augrom
Thesis submitted to the Faculty of the Graduate School of the 
University of Maryland, College Park in partial fulfillment
of the requirements for the degree of 
Master of Arts
2005
Advisory Committee:
 James Hagberg Professor, Chair/Advisor
 Michael D. Brown, Associate Professor
 Stephen M. Roth, Assistant Professor
ii
ACKNOWLEDGEMENTS
I would like to thank my advisor, Dr. James Hagberg, for his assistance and 
guidance throughout the Master’s program and in the completion of this thesis.  I would 
also like to thank Dr. Michael Brown and Dr. Stephen Roth for their assistance, time, and 
support in serving on my thesis committee.  This project would not have been possible 
without the members of the GERS team, particularly Jennifer McKenzie, Tina Ellis and 
Dr. Dana Phares, as their assistance was greatly appreciated. I would also like to extend a 
special thanks to all of the participants of the GERS study for their hard work and 
dedication.  
Finally, without the loving support of my parents, friends, and especially Neil, 
this project would not have been possible.  They have been able to help me through these 
stressful times and offer unending encouragement.
iii
TABLE OF CONTENTS
LIST OF TABLES iv
LIST OF ABBREVIATIONS v
CHAPTER 1: INTRODUCTION
    Research Question
    Hypotheses
1
5
CHAPTER 2: METHODS
   Subjects and Sampling
Experimental Design and Variables
Instrumentation
Data Collection Procedures
Statistical Analysis
CHAPTER 3: RESULTS 13
   Baseline Population Comparisons
   Comparison of Training Adaptations
CHAPTER 4: DISCUSSION 25
CHAPTER 5: CONCLUSION 33
APPENDIX A:  PROPOSAL INFORMATION 35
   Statement of the problem
Experimental hypotheses
   Delimitations
   Limitations
   Operational definitions
APPENDIX B:  LITERATURE REVIEW
The Metabolic Syndrome
Heritability of the Metabolic Syndrome and its Components
Effects of Exercise Training
Heritability of Exercise Training Adaptations                                     
Nuclear Lamina
Lamins A & C
The C1908T Polymorphism
Summary
References – Literature Review
38
APPENDIX C: INFORMED CONSENT FORM 58
REFERENCES 63
iv
LIST OF TABLES
Table 1.  Allele and Genotype Frequencies for LMNA C1908T 
Polymorphism – Baseline Comparison Population
15
Table 2. Subject Characteristics as a Function of LMNA C1908T 
Polymorphism Genotype Groups – Baseline Comparison Population
15
Table 3. Body Composition Variables as a Function of LMNA C1908T 
Polymorphism – Baseline Comparison Population
16
Table 4. Plasma Lipoprotein-Lipid Variables as a Function of LMNA 
C1908T Polymorphism Genotype Groups– Baseline Comparison 
Population
17
Table 5. OGTT Variables as a Function of LMNA C1908T 
Polymorphism Genotype Groups– Baseline Comparison Population
18
Table 6. Allele and Genotype Frequencies for LMNA C1908T 
Polymorphism – Exercise Training Population
21
Table 7. Subject Characteristics as a Function of LMNA C1908T 
Polymorphism Genotype Groups – Exercise Training Population  
21
Table 8. Exercise Training Induced Changes in Body Composition 
Variables as a Function of LMNA C1908T Polymorphism Genotype 
Groups – Exercise Training Population
22
Table 9. Exercise Training Induced Changes in Plasma Lipoprotein-
Lipid Variables as a Function of LMNA C1908T Polymorphism 
Genotype Groups – Exercise Training Population
23
Table 10. Exercise Training Induced Changes in OGTT Variables as a 
Function of LMNA C1908T Polymorphism Genotype Groups –
Exercise Training Population
24
Table 11. Allele and genotype frequencies 30
vLIST OF ABBREVIATIONS
AVF abdominal visceral fat
ANCOVA analysis of covariance
ANOVA analysis of variance
AD-EDMD autosomal dominant Emery-Dreifuss muscular dystrophy
BMI body mass index
CVD cardiovascular disease
DCM dilated cardiomyopathy
FPLD Dunnigan’s familial partial lipodystrophy
EDMD Emery-Dreifuss muscular dystrophy
EDTA ethylenediaminetetraacetic acid
FPG fasting plasma glucose
FPI fasting plasma insulin
FM fat mass
HDL-C   high-density lipoprotein
HRT hormone replacement therapy
INM inner nuclear membrane
ISI insulin sensitivity
LMNA lamin A/C
LM lean mass
LGMD1B limb girdle muscular dystrophy type 1B
LDL low-density lipoprotein
MAD Mandibuloacral Dysplasia
vi
NE nuclear envelope
OGTT oral glucose tolerance test
%FM percentage of fat mass
SNP single nucleotide polymorphism
TC total cholesterol
TG triglycerides
VLDL very-low-density lipoprotein
1CHAPTER 1: INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death among Americans, 
accounting for 38% or 1 out of every 2.6 deaths in the United States in 2002 (3). More 
than 70 million Americans have one or more types of CVD and 27 million of those 
affected are over the age of 65. The estimated cost of CVD in the US is $393.5 billion in 
the year 2005. Risk factors for CVD include diabetes, obesity, dyslipidemia, hypertension 
and physical inactivity (3). 
 A risk factor of CVD, type 2 diabetes mellitus, is caused by a combination of 
insulin resistance and insufficient insulin secretion by the pancreas. Insulin resistance, the 
result of obesity and physical inactivity, is accompanied by dyslipidemia and increased 
prothrombotic factors (15). The combination of these factors, which are the predecessors 
of type 2 diabetes and risk factors for CVD, is called the metabolic syndrome. The 
metabolic syndrome, its components, and type 2 diabetes have all been shown to be the 
result of both environmental and genetic factors (8; 31). 
 Many genome-wide scans have been conducted to determine specific 
chromosomal loci that, along with environmental factors, pre-dispose individuals to type 
2 diabetes and related phenotypes. Susceptibility loci for type 2 diabetes have been 
identified on chromosome 1q21-24 in French Whites, British Whites, Chinese and Old 
Order Amish populations (37; 40; 43; 20). Lamin A/C (LMNA), a gene located in this 
region, is associated with familial partial lipodystrophy, a condition characterized by 
severe insulin resistance, diabetes, dyslipidemia and atherosclerosis, making it an 
exceptional positional candidate gene for type 2 diabetes and related phenotypes (7).
2The LMNA gene products, lamins A and C, are important elements of the nuclear 
lamina. The nucleus of higher eukaryotic cells is comprised of three parts: the nuclear 
membranes, nuclear pore complexes, and the nuclear lamina. The lamina, associated with 
the inner nuclear membrane, is a structural component and also functions in DNA 
replication and chromatin organization (27). The lamina consists of proteins (called 
lamins) arranged in a fibrous network. There are two classes of nuclear lamins in human 
cells identified as lamin A or B (27). The LMNA gene encodes proteins that produce the 
two major A-type lamins; lamin A and lamin C (27). Human lamins A and C are identical 
in the initial 566 amino acids at which point alternative splicing in the LMNA gene 
results in two similar but functionally different isoforms (23) .
As already stated nuclear lamins A and C function as structural components of the 
nuclear membrane and also play a role in DNA replication. Mutations in the LMNA A/C 
gene are collectively referred to as laminopathies. Mutations in the genes that code for A 
type lamins result in these inherited laminopathies (27). Tissues that are affected by 
mutations in lamins A and C include peripheral nerves, striated muscle and adipose 
tissue. Mutant lamins expressed in cultured cells have been shown to disrupt the lamina 
structure which, in turn, impairs DNA synthesis (26; 33) and inhibits RNA polymerase II 
activity (33). Specifically, mutations in lamin A/C have been related to Emery-Dreifuss 
muscular dystrophy (5), Limb girdle muscular dystrophy type 1B (28), dilated 
cardiomyopathy (11), Charcot-Marie-Tooth neuropathy type 2 B1 (9) and Dunnigan’s 
familial partial lipodystrophy (7).
Dunnigan’s familial partial lipodystrophy (FPLD), a rare autosomal-dominant 
disease, is characterized by complete or partial absence of adipose tissue. Patients with 
3FPLD have normal fat distribution until they reach puberty, at which point adipocytes in 
their trunk and extremities degenerate (6; 13; 21) . Another characteristic of FPLD is 
insulin resistance, which is associated with dyslipidemia and often precedes type 2 
diabetes (16). 
A genetic variation in lamin A/C has also been reported to be associated with 
obesity-related anthropometric and biochemical traits in aboriginal Canadians and Inuit 
(17; 18), higher fasting triglyceride, lower HDL-cholesterol concentrations and the 
metabolic syndrome in an Amish population (34) and reduced subcutaneous abdominal 
adipocyte size in Pima Indians (39). Specifically, the mutation is a common single 
nucleotide polymorphism (SNP) in exon 10 of LMNA. This silent CT substitution 
occurs at nucleotide 1908 and affects the third base within codon 566, which is also the 
last codon shared between lamins A and C before alternative splicing produces one of 
these proteins (17). Exercise training has been shown to have a positive effect on all of 
the above mentioned factors which are a result of the C1908T SNP and independently 
contribute to type 2 diabetes and cardiovascular disease. The interactive effect of exercise 
training and this polymorphism has not yet been investigated. 
STATEMENT OF THE PROBLEM
The purpose of this project was to determine the effect that the C1908T 
polymorphism has on body composition, plasma lipoprotein profile and insulin 
sensitivity in sedentary subjects before, and their changes with, 24-weeks of exercise 
training.
4EXPERIMENTAL HYPOTHESES
1. Subjects carrying the C-allele will have significantly better  body 
composition, plasma lipoprotein profile and insulin sensitivity at baseline.
2. After 24 weeks of exercise training subjects carrying the C-allele will have 
significantly less improvement in body composition, their plasma lipoprotein 
profile and insulin sensitivity.
5CHAPTER 2: METHODS AND PROCEDURES
SUBJECTS AND SAMPLING
The subjects for this study were participants in the Gene Exercise Research Study 
at the University of Maryland, College Park. These subjects were volunteers from the 
Washington, D.C. metropolitan area who responded to media advertisements (newspaper 
and magazine advertisements, radio public service announcements, flyers mailed to 
citizens in the metropolitan area).  Subjects initially took part in a telephone screening 
interview to confirm that they met the following criteria: sedentary, nondiabetic, 
nonsmoking, no history of CVD or lung disease, normotensive or hypertensive with 
blood pressure <160/90 controlled with non-lipid and non-glucose altering medication, 
aged 50 to 75 years, no history of liver or kidney disease, no history of ulcers or other 
bleeding disorders, a hematocrit greater than 35, a body mass index (BMI) less than 37 
kg/m
2
, and no physical or orthopedic conditions that would preclude exercise.  In 
addition, women were required to be postmenopausal and agreed to maintain their 
hormone replacement therapy (HRT) status, either receiving or not receiving HRT. It was 
necessary that all of the subjects meet these criteria to ensure that subjects had no known 
conditions limiting participation in any of the testing procedures and to aid in the control 
of extraneous variables that could affect body composition, plasma lipoprotein-lipid
levels and insulin sensitivity.  In addition, individuals aged 50-75 were chosen as the 
subject population since they are a high risk group for CVD and preventive measures 
could make an impact on their health. 
6EXPERIMENTAL DESIGN AND VARIABLES
This study was a retrospective analysis of data from the subjects of the Gene 
Exercise Research Study at the University of Maryland, College Park. This study 
examined the differences in body composition, plasma lipoprotein-lipid levels and insulin 
sensitivity in 50-75 year old individuals, grouped by genotype for a single nucleotide 
polymorphism in exon 10 of the Lamin A/C gene. In addition, gender, age, HRT status,
ethnicity, body composition and baseline values were accounted for as covariates in this
study. 
INSTRUMENTATION
     Since, the purpose of this study was to determine genotypic effects associated with 
differences in body composition, plasma lipoprotein-lipid levels and insulin sensitivity,
the independent variable was a gene having associations with body composition 
measures, plasma lipoprotein-lipid levels and insulin sensitivity.  Furthermore, the gene 
examined has a common genetic polymorphism, which served as levels of the 
independent variable.  The independent variable was the C1908T polymorphism.  
Genotyping took place in Dr. Robert Ferrell’s laboratory at the University of Pittsburgh, 
Pittsburgh, PA.  To ensure validity, test samples were genotyped by direct comparison to 
controls of known genotype on the same gel.  Additionally, two independent observers 
scored the gels to ensure that the correct genotype was determined.
The dependent variables of the study were initial percent body fat, intra-
abdominal fat, subcutaneous fat, trunk fat, plasma lipoprotein-lipid levels, fasting plasma 
glucose, fasting plasma insulin and insulin sensitivity index, changes in percent body fat, 
intra-abdominal fat, subcutaneous fat, trunk fat, plasma lipoprotein-lipid levels, fasting 
7plasma glucose, fasting plasma insulin and insulin sensitivity index, that occurred  after 24 
weeks of exercise training.
DATA COLLECTION PROCEDURES
Screening 
     This study took place following approval by the University of Maryland, College Park 
Institutional Review Board.  Initially, written informed consent was obtained from all 
individuals interested in participating in the Gene Exercise Research Study, which had
been approved by the Institutional Review Board at the University of Maryland, College 
Park.  The following procedures took place during each potential subject’s first 
laboratory visit. Medical history was examined and height and weight were measured to 
calculate BMI.  Following an overnight fast of 12 hours, a blood sample wa s drawn for 
cholesterol, genotype, and glucose measurements.  Standard blood chemistry tests were 
used to assess liver, kidney, and blood disorders and a 2-hour, 75 gram oral glucose 
tolerance test (OGTT) was performed to assess diabetes status.  As inclusion criteria, 
subjects must have had a fasting glucose of less than 126 milligrams per deciliter 
(mg/dL), a 2-hour glucose less than 200 mg/dL, and at least one National Cholesterol 
Education Program lipid abnormality (cholesterol greater than 200 mg/dL, HDL less than 
35 mg/dL, triglyceride greater then 200 but less than 400 mg/dL, or LDL greater than 130 
mg/dL).  Individuals who met inclusion criteria after the first laboratory visit underwent a 
second screening visit. The second screening visit consisted of a general physical 
examination and a maximal graded treadmill exercise test, using the Bruce protocol, to 
screen for CVD.  Blood pressure, electrocardiogram, and heart rate were recorded before 
the test, at the end of every stage in the test, and every other minute for 6 minutes during 
8active recovery from the exercise test.  During this screening visit a potential subject was
excluded from the study if his or her blood pressure response to exercise was abnormal, 
the test was terminated due to cardiovascular symptoms, or the subject had ST segment 
depression greater than 2 mV (1).
Dietary Stabilization
After successfully completing the screening process, subjects attended dietary 
lessons on the principles of the AHA Step 1 diet, twice a week for six weeks. The 
emphasis of the AHA Step 1 diet includes consuming 55-60% of dietary calories from 
carbohydrate sources, less than 30% of dietary calories from fat sources, less than three 
grams of salt per day and consuming alcoholic beverages in moderation (2). Subjects 
were required to maintain the AHA Step 1 diet throughout their participation in the study. 
Periodically diet recalls and food frequency questionnaires were completed by subjects 
and reviewed by a registered dietician to ensure compliance. Additionally, subjects were 
instructed to maintain caloric intake throughout the study, since weight loss can influence 
many health and fitness variables. Subjects were weighed weekly and those losing more 
weight than expected or gaining weight were advised in properly increasing or decreasing 
their daily calories.
Baseline Testing
After completing the dietary stabilization program, subjects underwent two body 
composition scans. Total body composition was measured via dual energy x-ray 
absorptiometry (DPX-L, Lunar Corporation, Madison, WI) using standard procedures 
(19; 25).  Subjects were measured in the fasted state using either the slow or medium 
scan mode (depending on the subject’s size).   Intra-abdominal fat was quantified midway 
9between L4 and L5 using computerized tomography as described previously (29).
Visceral and subcutaneous adipose tissue areas were delineated by encircling the 
abdominal muscular wall.  Both adipose tissue areas were calculated from the pixel 
distribution with attenuation values -190 and -30 Hounsfield units.
Following a 12-hour overnight fast, plasma samples were drawn and plasma 
lipoprotein-lipid profiles were determined. Plasma samples were drawn on two separate 
occasions and the values were averaged. If the values differed by more than 10%, a third 
separate measurement was included in the average. A CDC-standardized Hitachi 717 
autoanalyzer was used to enzymatically measure plasma triglyceride and total cholesterol 
levels. LDL-C was calculated using the Friedewald equation (12) and HDL-C was 
measured after precipitation with dextran sulfate (38). A second precipitation using 
dextran sulfate was used to separate HDL2 and HDL3 (14). HDL2-C was calculated as the 
difference between total HDL-C and HDL3-C. 
 A 2-hour OGTT was performed following a 12-hour overnight fast. Subjects were 
asked to refrain from using anti-inflammatory medications for 24-hours before the test 
and to consume at least 250 grams of carbohydrate per day for the 3 days prior to the 
OGTT. Subjects recorded all food consumed in the 3 days prior to the OGTT and the 
records were collected and examined to ensure adequate carbohydrate intake. A 20- or 
22-gauge indwelling venous catheter was placed in the antecubital vein, and blood 
sampling occurred before and every 30 minutes for 2-hours following the ingestion of a 
75 gram glucose solution. The blood samples were collected in tubes containing 
potassium ethylenediaminetetraacetic acid (EDTA) and centrifuged at 4 degrees Celsius. 
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Plasma samples were then separated and stored at -80 degrees Celsius until assayed for 
glucose and insulin.
Plasma glucose levels were analyzed with a glucose analyzer (2300 STAT Plus, 
YSI, Inc., Yellow Springs, OH) using the glucose oxidase method. Plasma insulin levels 
were determined by radioimmunoassay (HI-14K kit, Linco Research, Inc., St. Charles, 
MO). Insulin sensitivity index was calculated using an equation developed by Matsuda 
and DeFronzo. (24). 
Genotyping
The blood sample for genotyping was drawn during the screening process.  All 
genotyping took place in the laboratories of Dr. Robert Ferrell at the University of 
Pittsburgh, Graduate School of Public Health, using standard techniques. Briefly, DNA 
was isolated from peripheral lymphocytes and genotyping for LMNA was carried out by 
amplification of the target sequence using polymerase chain reaction. The amplified 
product was digested with the restriction enzyme NlaIII, separated on polyacrylamide 
gels, and then stained and visualized under ultraviolet light (17). 
Exercise Training Intervention
Subjects completed 24-weeks of exercise training by attending three supervised 
exercise sessions per week. During exercise sessions heart rate monitors were worn to 
control exercise intensity and blood pressure was assessed before, during and after 
exercise. Exercise modes included treadmill, stair climber, elliptical, rower, cycling and 
skiing. Initially, exercise sessions consisted of 20-minutes at 50% VO2max. Exercise 
duration increased five-minutes each week until week five; at this time subjects were 
completing 40 minutes of 50% VO2max exercise each session. Exercise intensity was then 
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increased by 5% each week until an intensity of 70% VO2max was reached. When subjects 
reached week ten an additional 45-60 minute exercise session at less then 70% VO2max
was added. Exercise heart rate, mode and duration were recorded after each session in a 
logbook.
Final Testing
Following completion of the exercise training, subjects submitted a final seven-
day diet record to ensure their adherence to the AHA Step 1 diet prior to reassessment of 
the plasma lipoprotein-lipid profile, body composition, insulin sensitivity and VO2 max. 
Subjects continued with the exercise training until all final tests were completed;
additionally, blood samples for plasma lipoprotein-lipid profile and the 2-hour OGTT 
were drawn 24-36 hours after an exercise session.
STATISTICAL ANALYSES 
All comparisons were made between C-allele carriers and TT homozygotes. Chi 
square tests were used to determine if genotype frequencies were in Hardy-Weinberg 
equilibrium and to compare potential differences in gender and female HRT status 
between groups. Analysis of variance (ANOVA) mean comparison procedures were used 
to examine differences in subject characteristics and plasma lipoprotein-lipid levels, body 
composition and insulin sensitivity at baseline and their changes with training. Analysis 
of covariance (ANCOVA) was used to account for other variables influencing body 
composition, plasma lipoprotein-lipid levels and insulin sensitivity index. Any 
differences found in baseline variables using ANOVA were re-analyzed with age, gender, 
HRT status, ethnicity and body composition as covariates. Any differences found in 
change with training variables using ANOVA were re-analyzed with age, gender, HRT 
12
status ethnicity, body composition and baseline level of that variable as covariates. All 
statistical analyses were performed using SAS. Statistical significance was set at p0.05 
level.
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CHAPTER 3: RESULTS
Baseline Population Comparisons
The sample size for hypothesis #1, which compared percent body fat, plasma 
lipoprotein-lipid profile and insulin sensitivity across LMNA genotypes at baseline, 
ranged from 33-46 for the C allele carriers and 58-98 for the TT homozygotes. There 
were 56 male subjects and 88 female subjects. Of the 88 female subjects, 43 were using 
HRT. The ethnicity of the subject population was 75% Caucasian (n = 108), 17% 
African-American (n = 25), 5% Asian (n = 7), 2% Hispanic (n = 3) and 1% other (n = 1).
Baseline population allele and genotype frequencies for the LMNA C1908T 
polymorphism are displayed in Table 1. The T and C allele frequencies were 0.68 and 
0.32, respectively. Of the 144 subjects, 68% (n = 98) were TT homozygotes, 29 % (n = 
41) were CT heterozygotes, and 3% (n = 5) were CC homozygotes.  The genotype 
frequencies did not differ from those predicted by Hardy-Weinberg equilibrium (2 = 
0.08, P >0.05). However, the genotypes were regrouped for statistical analysis as C allele 
carriers versus TT homozygotes as there were only 5 CC homozygotes. Subject 
characteristics for the genotype groups are shown in Table 2. General linear ANCOVA 
techniques, with age, gender, ethnicity and baseline percent body fat as covariates, were 
used to analyze all data for hypothesis #1.
There were no significant differences between the LMNA genotype groups with 
regard to body composition variables at baseline as shown in Table 3, although the TT 
homozygotes tended to have a slightly more favorable body composition than the C allele 
carriers, in terms of intra-abdominal fat, subcutaneous fat area, trunk fat, and total body 
fat; however, none of these differences were statistically significant.
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As shown in Table 4, there were no significant differences among the LMNA 
genotype groups relative to baseline plasma lipoprotein-lipid variables. The TT 
homozygotes tended to have a less favorable lipid profile with higher total cholesterol, 
triglycerides and LDL and lower HDL and HDL2, however, these differences were not 
significant. While the baseline values for HLD2 are approximately 60% higher in the C 
allele group, this difference was not significant. 
There were no significant differences between the C allele carriers and TT 
homozygotes with regard to OGTT variables at baseline as shown in Table 5. The insulin 
sensitivity and fasting plasma glucose values were almost identical between the genotype 
groups. There appears to be no trend toward differences between the genotype groups 
with respect to the OGTT variables. 
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Table 1. Allele and Genotype Frequencies for LMNA C1908T Polymorphism – Baseline 
Comparison Population
Table 2. Subject Characteristics as a Function of LMNA C1908T Polymorphism 
Genotype Groups – Baseline Comparison Population
LMNA Genotype Group
Characteristics TT (n = 98) CT/CC (n = 46)
Men/Women 41/57 15/31
Women on/not on 
HRT
27/30 16/15
White/Non-White 71/27 37/9
Age 
(years)
57.3±0.5 58.6±0.9
Height 
(cm)
169.3±1.0 166.0±1.3
Weight 
(kg)
81.5±1.5 80.1±2.0
Body Fat 
(%)
36.6±1.0 39.0±1.4
Note: Values are expressed as counts or least-squares means ± SEM. Probabilities 
calculated from 2, Fishers Exact tests or ANOVA. All differences between genotype 
groups were not significant. 
Allele Frequency Genotype Frequency
T  0.68  (n = 98)
C  0.32  (n = 46)
TT 0.68  (n = 98)
CT 0.29  (n = 41)
CC 0.03   (n = 5)
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Table 3. Body Composition Variables as a Function of LMNA C1908T Polymorphism –
Baseline Comparison Population
LMNA Genotype Group
Characteristics TT CT/CC 
CTIA
(cm2)
124.9±4.7 123.7±5.1 
CTSC
(cm2)
350.6±14.5 361.4±18.2 
TRUNK FAT
(%)
39.0±0.9 40.3±1.2 
TOTAL FAT
(%)
38.9±1.0 40.1±1.4 
Note: Values are expressed least-squares means ± SEM. Probabilities calculated from 
ANCOVA. All differences between genotype groups were not significant. Number of 
subjects for TT genotype group ranged from 89 – 98. Number of subjects for CT/CC 
genotype group ranged from 42 – 46.
17
Table 4. Plasma Lipoprotein-Lipid Variables as a Function of LMNA C1908T 
Polymorphism Genotype Groups – Baseline Comparison Population
LMNA Genotype Groups
Characteristics TT CT/CC
Total Cholesterol
(mg/dL) 213.4±3.3 209.0±5.6
LDL
(mg/dL) 133.1±2.8 126.2±4.7
HDL
(mg/dL) 49.1±1.4 52.1±2.8
HDL2
(mg/dL) 4.9±0.7 8.0±1.7
HDL3
(mg/dL) 44.1±1.0 43.9±1.4
Triglycerides
(mg/dL) 159.8±8.8 149.0±11.8
Note: Values are expressed least-squares means ± SEM. Probabilities calculated from 
ANCOVA. All differences between genotype groups were not significant. Number of 
subjects for TT genotype group ranged from 83 – 85. Number of subjects for CT/CC 
genotype group was 38.
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Table 5. OGTT Variables as a Function of LMNA C1908T Polymorphism Genotype 
Groups– Baseline Comparison Population
LMNA Genotype Groups
Characteristics TT CT/CC 
Fasting Plasma Glucose
(mg/dL)
92.3±1.3 92.7±1.9
Fasting Plasma Insulin
(pmol/L)
84.5±3.9 80.0±4.1
Insulin Sensitivity Index 1.6±0.7 1.6±0.1
Note: Values are expressed as least-squares means ± SEM. Probabilities calculated from 
ANCOVA.  All differences between genotype groups were not significant. Number of 
subjects for TT genotype group ranged from 58 – 74. Number of subjects for CT/CC 
genotype group ranged from 33 – 37.
Comparison of Training Adaptations
The sample size for hypothesis #2, which compared changes with exercise 
training in percent body fat, plasma lipoprotein-lipid profile and insulin sensitivity across 
LMNA genotypes, ranged from 23-33 for the C allele carriers and 49-71 for the TT 
homozygotes. There were 45 male subjects and 59 female subjects. Of the 59 female 
subjects, 29 were using HRT. The ethnicity of the population was 79% Caucasian (n = 
82), 14% African-American (n = 15), 5% Asian (n = 5), 1% Hispanic (n = 1) and 1% 
other (n = 1).
Allele and genotype frequencies for the exercise training population are presented 
in Table 6. The T and C allele frequencies were 0.68 and 0.32, respectively. Of the 104 
subjects, 68% (n = 71) were TT homozygotes, 28% (n = 29) were CT heterozygotes, and 
4% (n = 4) were CC homozygotes. The genotype frequencies did not differ from those 
predicted by Hardy-Weinberg equilibrium (2 = 0.23, P >0.05). The genotypes were 
regrouped for statistical analysis as C allele carriers versus TT homozygotes as there 
19
were only 4 CC homozygotes. Subject characteristics for these genotype groups are 
shown in Table 7. General linear ANCOVA techniques, with age, gender, ethnicity, final 
percent body fat and the baseline value of each variable as covariates, were used to 
analyze all data for hypothesis #2.
Among the exercise training population there were no significant differences 
between the genotype groups with regard to the change in body composition variables 
with exercise training as shown in Table 8. However, a significant difference was found 
for changes in intra-abdominal, trunk fat and total fat measurements with exercise 
training within the total population and within each of the genotype groups. Although 
both genotype groups decreased subcutaneous fat, there was not a significant difference 
between or within the LMNA genotype groups, with respect to changes in CTSC 
measurements with training as shown in Table 8.
As shown in Table 9, there was no significant difference within either of the 
genotype groups or the total population with regard to the change in total cholesterol or 
LDL cholesterol levels with exercise training. However, within the total exercise training 
population and each of the genotype groups, there was a significant change with exercise 
training in HDL-C, HDL2, HDL3 and TG. Triglyceride values were significantly 
decreased in both LMNA genotype groups and the total exercise population with exercise 
training and HDL-C, HDL2,  and HDL3  values were significantly increased with exercise 
training. 
There were significant differences with exercise training in some OGTT variables 
among both LMNA genotype groups and the total exercise training population as 
displayed in Table 10. Insulin sensitivity index improved with exercise training in both 
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LMNA genotype groups and the total exercise training population, as did fasting plasma 
insulin values. Fasting plasma glucose values, however, were not significantly improved 
with exercise training in any of the groups.
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Table 6. Allele and Genotype Frequencies for LMNA C1908T Polymorphism – Exercise 
Training Population
Table 7. Subject Characteristics as a Function of LMNA C1908T Polymorphism 
Genotype Groups – Exercise Training Population  
LMNA Genotype Groups
Characteristics TT (n = 71) CT/CC (n = 33)
Men/Women 31/40 14/19
Women on/not on 
HRT
16/24 13/6
White/Non-White 55/16 27/6
Age (years) 57.5±0.6 58.8±1.0
Height (cm) 169.8±1.1 167.2±1.6
Weight (kg) 79.3±1.7 78.5±2.4
Body Fat (%) 35.8±1.2 36.9±1.6
Note: Values are expressed as counts or least-squares means ± SEM. Probabilities 
calculated from 2, Fishers Exact test, or ANOVA. All differences between genotype 
groups were not significant. 
Allele Frequency Genotype Frequency
T  0.68  (n = 71)
C  0.32  (n = 33)
TT 0.68  (n =71)
CT 0.28  (n = 29)
CC 0.04   (n = 4)
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Table 8. Exercise Training Induced Changes in Body Composition Variables as a 
Function of LMNA C1908T Polymorphism Genotype Groups – Exercise Training 
Population
LMNA Genotype Groups
Characteristics Total Population TT Homozygotes CT/CC
CTIA (cm2)
Baseline
Final
Change
121.9±3.8
111.7±3.4
-10.6±2.3*
122.2±5.0
112.0±4.3
-10.9±2.8*
121.4±5.8
111.2±5.5
-10.2±4.5*
CTSC (cm2)
Baseline
Final
Change
316.9±12.5
310.3±11.6
-5.9±3.8
317.4±16.4
309.0±14.6
-9.2±4.7
316.0±18.1
312.8±19.3
-4.6±6.3
TRUNK FAT (%)
Baseline
Final
Change
37.4±0.8
35.5±0.8
-1.7±0.3*
37.2±1.0
35.4±1.0
-1.6±0.3*
37.8±1.3
35.7±1.3
-1.8±0.5*
TOTAL FAT (%)
Baseline
Final
Change
36.4±1.0
34.7±0.9
-1.4±0.2*
36.1±1.2
34.6±1.2
-1.3±0.2*
36.9±1.6
35.0±1.6
-1.5±0.3*
Note: Values are expressed as least-squares means ± SEM. Probabilities calculated from 
ANCOVA.  * indicates significant change with training within that group at p0.05. The 
number of subjects for the total population, TT homozygotes and C allele carriers ranged 
from 98-102, 66-69 and 32-33, respectively.
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Table 9. Exercise Training Induced Changes in Plasma Lipoprotein-Lipid Variables as a 
Function of LMNA C1908T Polymorphism Genotype Groups – Exercise Training 
Population
LMNA Genotype Groups
Characteristics Total 
Population
TT Homozygotes CT/CC
Total Cholesterol(mg/dL)
Baseline
Final
Change
207.8±3.2
206.6±3.1
-1.2±2.0
212.0±3.6
211.1±3.8
-0.9±2.4
198.8±6.2
197.0±5.2
-1.9±3.7
LDL (mg/dL)
Baseline
Final
Change
128.0±2.8
127.6±2.6
-0.2±1.9
131.9±3.2
131.7±3.2
-0.1±2.4
119.8±5.2
118.8±4.4
-0.9±3.4
HDL (mg/dL)
Baseline
Final
Change
48.0±1.4
51.1±1.5
3.4±0.5*
47.2±1.6
50.3±1.7
3.6±0.6*
49.8±2.9
52.6±3.2
2.8±0.8*
HDL2 (mg/dL)
Baseline
Final
Change
4.8±0.7
6.4±0.9
1.5±0.4*
4.0±0.7
5.7±0.9
1.4±0.6*
6.3±1.7
7.8±2.0
1.5±0.6*
HDL3 (mg/dL)
Baseline
Final
Change
43.1±0.9
44.9±0.9
1.9±0.5*
43.0±1.1
44.8±1.1
2.0±0.7*
43.2±1.5
45.0±1.5
1.8±0.8*
Triglycerides (mg/dL)
Baseline
Final
Change
157.5±7.9
141.8±6.6
-16.1±4.8*
164.5±10.0
146.8±8.1
-18.4±5.9*
142.5±12.5
131.2±10.9
-11.2±8.5*
Note: Values are expressed as least-squares means ± SEM. Probabilities calculated from 
ANCOVA.  * indicates significant change with training within that group at p0.05. The 
number of subjects for the total population, TT homozygotes and C allele carriers ranged 
from 101-104, 68-71 and 33, respectively.
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Table 10. Exercise Training Induced Changes in OGTT Variables as a Function of 
LMNA C1908T Polymorphism Genotype Groups – Exercise Training Population
.
LMNA Genotype Groups
Characteristics Total Population TT Homozygotes CT/CC
Fasting Plasma 
Glucose (mg/dL)
Baseline
Final
Change
91.4±1.1
92.8±1.2
1.3±1.2
90.7±1.2
92.2±1.2
1.5±1.3
93.0±2.2
94.0±1.8
1.0±2.0
Fasting Plasma 
Insulin (pmol/L) 
Baseline
Final
Change
81.2±3.5
70.1±2.5
-11.1±2.4*
83.0±4.6
72.0±3.2
-10.9±3.1*
77.3±5.0
66.0±4.1
-11.3±3.5*
Insulin Sensitivity 
Index
Baseline
Final
Change
1.5±0.1
1.7±0.1
0.2±0.1*
1.5±0.1
1.7±0.1
0.2±0.1*
1.4±0.1
1.7±0.1
0.2±0.1*
Note: Values are expressed as least-squares means ± SEM. Probabilities calculated from 
ANCOVA techniques.  * indicates significant change with training within that group at 
p0.05. The number of subjects for the total population, TT homozygotes and C allele 
carriers was 72, 49 and 23, respectively.
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CHAPTER 4: DISCUSSION
Studies have associated the LMNA C1908T gene polymorphism, specifically the 
T-allele, with increased occurrence of the metabolic syndrome, increased fasting TG, 
increased indices of obesity, and decreased HDL-cholesterol levels (34; 16; 18). 
Contrastingly, a study investigating this polymorphism in the Pima Indians found the T 
allele to be significantly associated with increased insulin sensitivity (39). In addition to 
genetic influences, exercise training has been shown to affect the metabolic syndrome 
and its components, therefore this study sought to examine differences in body 
composition, plasma lipoprotein-lipid profile, and insulin sensitivity index at baseline and 
the change in these variables with exercise training, between C allele carriers and TT 
homozygotes of the C1908T polymorphism. The results of this study indicated that there 
were no significant differences between the genotype groups at baseline or their change 
with training, regarding body composition, plasma lipoprotein-lipid profile, or insulin 
sensitivity index.
Hegele and colleagues reported that among a population of Oji-Cree Aboriginal 
Canadians, TT homozygotes had significantly higher indices of obesity (BMI, wasit:hip 
ratio) than the C allele carriers. The TT homozygotes also had a higher body fat 
percentage but this was not significantly different from the C allele carriers (17). Hegele 
and colleagues also reported on the association between anthropometric traits and the 
LMNA C1908T polymorphism among the Inuit Indians of Canada (18). They reported 
that subjects with the T allele had significantly higher body weight, BMI, waist 
circumference, waist-to-hip ratio, subscapular skinfold thickness and subscapular to 
triceps skinfold thickness ratio. These finding are consistent with their previous findings 
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among the Oji-Cree Aboriginal Canadians (17). Weyer and colleagues investigated an 
association between the LMNA C1908T polymorphism and various physical and 
metabolic characteristics among a population of Pima Indians (39). Their results show 
that among this population, the SNP is not associated with weight, percentage of body 
fat, or waist-to-thigh ratio. They did, however, find that TT homozygotes had a 10% 
smaller mean subcutaneous abdominal adipocyte size (39). 
In contrast to the findings of the previously mentioned studies, the TT 
homozygotes in our baseline population tended to have a slightly more favorable body 
composition, however these differences were not significant. Among the Pima Indian 
population, TT homozygotes had a significantly smaller mean subcutaneous adipocyte 
size, while adipocyte size was not measured in our subjects. Among the exercise training 
population from our study, the C allele carriers tended to show a greater improvement in 
body composition with exercise training, although again this improvement was not 
significantly different from that in the TT homozygotes. There was a significant 
improvement with exercise training within both genotype groups regarding intra-
abdominal fat, trunk fat and total body fat. Subcutaneous fat was lower in both groups 
following the exercise training, but these reductions were not significant.
Steinle and colleagues reported that the LMNA C1908T polymorphism was 
associated with the metabolic syndrome as well as higher fasting TG and lower HDL-C 
among a population of Old Order Amish subjects (34). Amish subjects carrying the T 
allele had less favorable lipid profiles and higher prevalence of the metabolic syndrome 
(34). 
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In our study, there was no significant difference between the C allele carriers and 
TT homozygotes regarding TG or HDL-C values at baseline, and although the TT 
homozygotes tended to have a less favorable lipid profile with higher TC, TG and LDL 
and lower HDL, these differences were not significant. After 24-weeks of exercise 
training TG levels were significantly lower and HDL-C was significantly higher within 
both genotype groups, although there was not a significant difference in the changes with 
exercise training between the two groups. While TC levels were also lowered in both 
genotype groups with exercise training, there was not a significant difference in these 
changes with training either between or within the two LMNA genotype groups  or the 
total exercise training population. 
In their investigation of the LMNA C1908T polymorphism in the Oji-Cree 
Aboriginal Canadians, Hegele and colleagues measured fasting plasma insulin (FPI), 
which was found to be somewhat lower in TT homozygotes; however, this difference was 
not significant. While Hegele et. al. reported taking fasting glucose samples, these results 
were not presented (17). Weyer and colleagues investigated an association between the 
LMNA C1908T polymorphism and metabolic characteristics among a population of Pima 
Indians (39). Their results show that in this population, the SNP is not associated with 
fasting insulin and glucose values. Additionally, Weyer et. al. reported that among the 
Pima Indians, the T allele was significantly associated with increased insulin sensitivity 
(39).
In our baseline population, the TT homozygotes and C allele carriers had almost 
identical FPI, FPG and insulin sensitivity index (ISI) values, and there were no 
significant differences between the genotype groups. Among the exercise training 
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population in our study, ISI and FPI improved significantly in both genotype groups 
following exercise training, but there was not a significant difference between the 
genotype groups. Exercise training did not significantly improve FPG within the 
genotype groups or the exercise training population.
The purpose of our study was to determine the effect of the C1908T 
polymorphism on body composition, plasma lipoprotein-lipid profile and insulin 
sensitivity. Our first hypothesis proposed that subjects in our baseline population carrying 
the C allele would have significantly lower percent body fat, a more favorable plasma 
lipoprotein-lipid profile and higher insulin sensitivity. This hypothesis was based upon 
the results of the previously discussed studies. Our results show that while there were 
some slight differences between the genotype groups in the baseline population, none of 
these differences were significant regarding any of the variables. 
Our second hypothesis proposed that after 24 weeks of exercise training subjects 
carrying the C allele would have significantly less improvement in percent body fat, 
plasma lipoprotein-lipid profile and insulin sensitivity. There have been no previous 
exercise training studies conducted concerning the LMNA C1908T polymorphism, 
therefore, this hypothesis was based upon the idea that if, in fact, the TT homozygotes 
had a less favorable profile relative to the components of the metabolic syndrome at 
baseline, they would have more room for improvement than the C allele carriers. Our 
results show that although both genotype groups improved with exercise training in 
relation to many of the variables, the TT homozygotes did not improve significantly more 
for any of the variables than the C allele carriers.
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There are a few differences between our study and those previously mentioned, in 
addition to the results. A large difference is the homogeneity of the populations. Each of 
the previously mentioned studies investigated a very ethnically homogeneous group, 
often times consisting of family members. In addition to the ethnic homogeneity, these 
other populations were geographically and/or culturally isolated for many generations 
which resulted in very similar eating and activity behaviors. The subjects in our study 
were not related and had a varied ethnicity. While a majority of the baseline population 
was Caucasian (75%), there were also African-American, Asian and Hispanic subjects. 
Statistical analysis for differences between ethnic groups relative to our variables was not 
conducted. Our protocol attempted to diminish the variability among subjects with regard 
to diet and exercise. Our subjects attended dietary classes to instruct them in the 
principles of the AHA Step 1 diet and submitted diet recalls at various stages of the 
study, however; all dietary information was self-reported. Additionally, subjects 
participated in structured and supervised exercise sessions three times a week for 24 
weeks. The structured dietary classes and exercise sessions were used to increase 
homogeneity among the subjects.
Another difference between our investigation and those previously mentioned 
involves the sample size and genotype and allele frequencies which are shown in Table 
11. Our investigation had the fewest number of subjects at 144, while the number of 
subjects in the other studies ranged from 186 to 908. Because of the small percentage of 
CC homozygotes (n = 5), our statistical analysis was conducted on C allele carriers 
versus TT homozygotes. As shown in Table 11, the only previous study to make 
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comparisons between all three genotype groups was Weyer et. al in their study on the 
Pima Indians (39).
Table 11.  Allele and Genotype Frequencies
Subjects Allele Frequencies Genotype Frequencies
Old Order Amish
n = 908
T allele carriers vs. CC homozygotes
(34)
C = 65%
T = 35%
CC = 42%
CT = 45%
TT = 12%
Oji-Cree Aboriginal Canadians
n = 306
C allele carriers vs. TT homozygotes
(17)
C = 23%
T = 77%
CC = 5%
CT = 36%
TT = 59%
Inuit Canadians
n = 186
T allele carriers vs. CC homozygotes
(18)
C = 52%
T = 48%
CC = 23%
CT = 58%
TT = 19%
Pima Indians
n = 255
compared all three genotype groups
(39)
C = 55%
T = 45%
CC = 29%
CT = 51%
TT = 20%
GERS – Baseline
n = 144
C allele carriers vs. TT homozygotes
C = 32%
T = 68%
CC =  3%
CT = 29%
TT = 68%
GERS – Exercise Training
n = 104
C allele carriers vs. TT homozygotes
C = 32%
T = 68%
CC =  4%
CT = 28%
TT = 68%
Another difference between our study and the previous studies was the inclusion 
of an exercise training intervention. Exercise training has been shown to improve the 
components of the metabolic syndrome that we investigated and among our subjects 
various body composition, plasma lipoprotein-lipid and OGTT variables were improved 
to a substantial extent with exercise training. However, the extent of improvement or 
change in these variables with exercise training did not differ significantly between the 
genotype groups.
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It is not yet clear how mutations in the lamin A and C proteins, which are 
expressed in nearly all differentiated somatic cells, cause different diseases. The current 
hypotheses which have been proposed to address this question are the mechanical stress 
or structural hypothesis and the gene-expression hypothesis.
The structural hypothesis suggests that mutations in lamins causing abnormalities 
in nuclear structure lead to increased susceptibility of cellular damage due to physical 
stress. This physical stress is likely to occur in skeletal and cardiac muscles where 
contractile forces are present. Lammering and colleagues studied LMNA deficient mice 
and found that the lack of A-type lamins compromised the structural integrity of the 
nuclear envelope. These cells were susceptible to stress-induced damage which led to 
loss of cell viability (22). Further support for this hypothesis is presented by Stewart et 
al., (36) who also studied LMNA knockout mice. These mice developed cardiac 
myopathies and skeletal abnormalities which resembled EDMD and also showed changes 
in peripheral nerve axons, but did not show signs of lipodystrophy. Despite the evidence 
supporting this hypothesis there are some limitations to it. For example, weakening of the 
nucleus is less likely to account for defects in adipose tissue because there is a lack of 
mechanical stress in this type of tissue (27).
The gene-expression hypothesis proposes that mutations in A-type lamins, which 
are important regulators of gene-expression, will alter their interaction with various 
regulatory proteins and ultimately promote disease in different tissues (42). Lamins 
interact with many nuclear factors, help regulate transcription and influence the
organization of heterochromatin. Changes in chromatin organization that have been 
observed in LMNA knockout mice and AD-EDMD patients could lead to altered tissue 
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specific gene-expression (30). Stierle et al. showed that there are two peptide regions of 
lamins A and C that take part in DNA-binding and alterations in this interaction may 
cause some laminopathies (35). 
The gene-expression hypothesis may be useful in explaining lipodystrophy disorders 
where the mechanical stress hypothesis had its inadequacies. While LMNA deficient 
mice have been shown to develop cardiomyopathy and muscular dystrophy they do not
exhibit lipodystrophy or insulin resistance, suggesting that lipodystrophy is not caused by 
loss of lamin A or C function. Fibroblasts from lipodystrophy affected individuals display 
alterations in chromatin structure suggesting the mutations causing lipodystrophies 
obstruct the regulation of adipocyte-specific gene expression (4).
Some limitations in this study should be noted. The sample size for our study was 
smaller than other studies investigating this polymorphism and we were not able to 
compare all three genotype groups. The lack of influence of the C1908T polymorphism 
may be due to small sample size and the grouping of subjects into two genotype groups. 
Analyzing each genotype group separately, with adequate sample sizes, may enable 
detection of significant differences. 
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CHAPTER 5: CONCLUSION
To conclude, the LMNA C1908T polymorphism does not appear to be associated 
with the baseline or change with training values of body composition, plasma lipoprotein-
lipid and OGTT variables. However, more research is needed, particularly with a larger 
sample size of rare allele carriers. Future studies should focus on obtaining a more 
balanced study population across genotype groups and examine other prospective 
candidate genes for interactions. Finally, the effect of genes on body composition, plasma 
lipoprotein profile and insulin sensitivity merits further study.
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APPENDIX A
PROPOSAL INFORMATION
Statement of the Problem
The purpose of this project was to determine the effect of the C1908T 
polymorphism on body composition, plasma lipoprotein profile and insulin sensitivity in 
sedentary subjects before, and their changes with, 24-weeks of exercise training.
Experimental Hypothesis
1. Subjects carrying the C-allele will have significantly more favorable body 
composition, plasma lipoprotein profile and higher insulin sensitivity at baseline 
2. After 24 weeks of exercise training subjects carrying the C-allele will have 
significantly less improvement in body composition, their plasma lipoprotein 
profile and insulin sensitivity.
Delimitations
1. Subjects for the study ranged in age from 50 to 75 years and have taken part in the 
Gene Exercise Research Study at the University of Maryland, College Park.
2. As members of the Gene Exercise Research Study, the subjects have been 
recruited from the University of Maryland and Washington D.C. metropolitan 
areas.
3. As participants in the Gene Exercise Research Study, the subjects were 
nonsmoking, nondiabetic, sedentary, healthy with the exception of having high 
cholesterol levels, calculated as having a body mass index less than 37 kilograms 
per meter squared (kg/m2), not taking medications known to affect glucose levels, 
and postmenopausal, if female.
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Limitations
1. The subjects recruited as part of the Gene Exercise Research Study were from the 
University of Maryland, College Park and Washington D.C. metropolitan areas 
and may not be representative of the entire population.
2. The frequencies of genotypes were not controlled, so rare allele carriers were 
grouped together in the analyses because sample sizes were inadequate.
3. This study is retrospective in nature.
Operational Definitions
1. Glucose – A monosaccharide containing six-carbon atoms that is used as a major 
energy substrate in the body.
2. Insulin – A pancreatic hormone secreted by the islets of Langerhans involved in 
the control of blood glucose levels by promoting the uptake and storage of 
glucose in the body. 
3. Oral Glucose Tolerance Test – Diagnostic assessment measuring the ability of the 
body to maintain euglycemia in response to a glycemic challenge.
4. Genetic Polymorphism – Common variation in genes at the DNA level.
5. Allele – Alternative form of a DNA sequence at a given locus.
37
APPENDIX B:  LITERATURE REVIEW
The Metabolic Syndrome
Heritability of the Metabolic Syndrome and its Components
Effects of Exercise Training
Heritability of Exercise Training Adaptations
Nuclear Lamina
Lamins A & C
The C1908T Polymorphism
Summary
References
38
APPENDIX B
  LITERATURE REVIEW
Previous studies have suggested that the C1908T polymorphism of the Lamin 
A/C gene (LMNA) may be associated with obesity, unfavorable plasma lipoprotein lipid 
profiles and the metabolic syndrome in certain populations. Exercise training has also 
been shown to affect these cardiovascular disease (CVD) risk factors. Accordingly, the 
role of the C1908T polymorphism and exercise training in the development and treatment 
of the previously mentioned CVD risk factors will be the focus of this review.
The Metabolic Syndrome 
Insulin resistance and obesity, in conjunction with dyslipidemia, is referred to as 
the metabolic syndrome. The metabolic syndrome affects approximately 25% of adults 
over the age of 20 and up to 45% of adults over 50.  The components of this syndrome, 
which serve as risk factors for type II diabetes mellitus and CVD, in addition to having 
environmental propensity, may be the result of genetic susceptibility (4; 42). 
Insulin resistance and Obesity
Insulin resistance, to which obesity and physical inactivity contribute, is caused 
by a combination of insulin resistant cells and insufficient insulin secretion by the 
pancreas. The normal response to an increase in blood glucose levels after a meal 
involves release of insulin from the pancreas. Insulin facilitates the diffusion of glucose 
into a cell by binding with receptors. Once insulin is bound to the cell, glucose can enter, 
where it is either used for energy or stored for later use. By facilitating the diffusion of 
glucose into a cell, insulin aids in the maintenance of normal blood glucose levels. When 
an individual is insulin resistant, or has decreased insulin sensitivity, the normal amount 
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of insulin secreted does not assist the diffusion of glucose into the cell. The pancreas 
overproduces insulin in response to increased blood glucose levels, which is referred to as 
hyperinsulinemia. Despite the overproduction of insulin a high blood glucose level is 
maintained and often leads to type 2 diabetes. Obesity contributes to insulin resistance 
because as adipocytes increase in size insulin receptor density decreases (14). 
Dyslipidemia
Dyslipidemia is characterized by increased levels of triglyceride, total cholesterol 
and LDL in conjunction with decreased HDL concentrations. Lipoproteins, formed in the 
liver from the union of triglycerides, phospholipids or cholesterol with protein, are the 
main form for lipid transport in the blood. These compounds are divided into various 
classes based on their density: chylomicrons, high-density, low-density and very-low 
density. 
 Very-low-density lipoprotein (VLDL), which contains the highest percentage of 
lipid and therefore has the lowest density, transports triglycerides to adipose and muscle 
tissue. VLDL is degraded by lipoprotein lipase into low-density lipoprotein (LDL), which 
contains fewer lipids. LDL conveys cholesterol to the linings of the blood vessels to 
which it adheres, forming plaque. High levels of VLDL and LDL are associated with 
CVD (36). 
High-density lipoprotein (HDL-C) is produced by the liver and small intestine, 
and contains the largest percentage of protein and the lowest percentage of cholesterol 
and lipids. High-density lipoproteins protect against CVD by conveying cholesterol away 
from blood vessels and to the liver for eventual excretion (36). Numerous studies have 
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established an inverse relationship between the concentration of HDL-C and 
cardiovascular disease (18). 
Type II diabetes mellitus, the metabolic syndrome and their shared risk factors for 
CVD can, in many cases, be managed or altered markedly by aerobic exercise training. 
Heritability of the Metabolic Syndrome and its Components
The HERITAGE Family Study (HEalth, RIsk factors, exercise Training And 
GEnetics) has undertaken the task of studying the role of genetics in cardiovascular, 
metabolic, and hormonal responses to aerobic exercise training. Their subjects consist of 
90 Caucasian families and 40 African-American families. The families, consisting of 
both parents and at least three biological adult offspring, participated in the same 20-
week exercise training program (5). 
Results from the HERITAGE Family Study show that the metabolic syndrome 
significantly accumulates within families (33). Additional reports from the HERITAGE 
Family Study show that genetic influences play a role in insulin levels, abdominal 
visceral fat and plasma lipoprotein- lipid profile. (25; 13).  
Heritability of Dyslipidemia
Pollin et al., investigated the heritability of plasma lipoprotein-lipid levels among 
28 Old Order Amish families. The specific variables studied included total serum 
cholesterol, high density lipoprotein cholesterol, triglycerides and low-density lipoprotein 
cholesterol. Linkage analyses indicated that lipid levels were substantially heritable 
among the Old Order Amish (39). Austin et al., also established the heritability of plasma 
lipoprotein-lipid levels among Japanese Americans. Results reveal that in this population 
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52% of the variation in plasma lipoprotein-lipid levels is attributable to genetic factors 
(3).
Heritability of Obesity
The role of genetics in determining body composition has also been investigated. 
Hong et. al. focused on the heritability of abdominal visceral fat (AVF) as it has been 
reported that AVF is a predictor of diabetes and correlates more strongly to insulin 
resistance than other indices of obesity in many studies. The heritability for AVF was 
found to be 42% among the 98 families investigated (23). Hsu et al. also examined the 
role of genetics in body composition. This study concentrated on percentage of fat mass 
(%FM), whole body fat mass (FM) and lean mass (LM) as measured by DEXA, in 
subjects from 244 families. Study outcomes show that %FM, FM and LM are 48%, 69% 
and 49% heritable, respectively (25). 
Effects of Exercise Training
Body Composition and Lipids
Exercise training has been shown to have a favorable impact on phenotypes 
associated with diabetes and the metabolic syndrome. Halverstadt et al., recently showed 
that body composition and plasma lipoprotein lipid profile improve significantly in men 
and women following 24-weeks of aerobic exercise training. The exercise training 
consisted of three sessions a week for 24-weeks. Training began with 20 minutes of 
exercise at 50% of VO2max and progressed to 40 minutes at 70% VO2max for the remaining 
14 weeks. At week 12 an additional exercise session lasting 45-60 minutes at a lower 
intensity was added. Among healthy, sedentary men and women, body weight, percent 
body fat and visceral adipose tissue decreased significantly following the exercise 
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training. Similarly, triglycerides decreased, while HDL-C levels increased (20). Review 
articles by Durstine et. al. and Poirier et. al. show that results similar to these have been 
found in numerous other laboratories as well (11; 38).
Insulin
A study by McKenzie et al., utilizing the same previously mentioned aerobic 
exercise training protocol, showed a significant increase in insulin sensitivity index as 
well as a decrease in fasting insulin with aerobic exercise training (34). Ryan et. al., 
indicates that these responses have also been found by other investigators (41). 
Heritability of Exercise Training Adaptations
Heritability of Changes in Insulin Values with Exercise Training
Adaptations to exercise training have also been shown to be heritable. Lakka et al. 
found strong evidence for linkage in fasting insulin response to aerobic exercise training. 
Using data from the HERITAGE Family Study, involving 99 white families and 105 
black families, this group measured fasting plasma glucose and insulin before and 
following 20-weeks of aerobic exercise training. Single and multipoint linkage analyses 
were performed on the phenotype data for baseline and final measures. No significant 
training effects were found for the glucose measures and subsequently this data was 
eliminated from the linkage analysis, however, insulin was found to decrease 
significantly following the aerobic exercise training. Changes in insulin levels with 
aerobic exercise training were shown to be heritable among both black and white families 
(31). 
Heritability of Changes in Plasma Lipoprotein-Lipid Values with Exercise Training
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Another investigation within the HERITAGE Family Study explored the 
heritability of plasma lipoprotein-lipid responses to aerobic exercise training. The data for
this study involved 99 white families and 115 black families whose plasma lipoprotein-
lipid profiles were assessed at baseline and following 20-weeks of training. Total 
cholesterol (TC), triglycerides (TG), very low-density lipoprotein (VLDL), low-density
lipoprotein (LDL-C) and high-density lipoproteins (HDL-C, HDL2-C, HDL3-C) were 
measured. There was significant family resemblance in the changes with training with 
approximately 30% of the phenotypic variance accounted for by familial factors (40). 
Heritability of Changes in Body Composition Values with Exercise Training
The heritability of changes in body composition with aerobic exercise training 
was examined among 99 white families participating in the HERITAGE Family Study. 
The outcome of this multipoint linkage analysis investigation showed that lean body 
mass, body fat content, and BMI changes with aerobic training were heritable. LOD 
scores between 2.0 and 3.0 indicate suggestive results and the LOD scores for change in 
percent body fat and fat mass were both 2.2 for a locus on chromosome 1. BMI presented 
an LOD score of 2.4 for a locus on chromosome 5 and fat-free mass showed an LOD 
score of 2.3 for a locus on chromosome 12 (9). 
Nuclear Lamina
The nuclear lamina, the innermost layer of the nuclear envelope (NE), is a fibrous 
meshwork composed of intermediate filament proteins called lamins. There are two 
classes of lamins; A-type and B-type. B-type lamins, B1 and B2, are encoded by the 
genes LMNB1 and LMNA2 respectively, while A-type, lamins A and C, arise by 
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alternative splicing of RNA encoded by a single gene, LMNA. The structure and function 
of A-type lamins will be discussed in detail in the following section. 
While perhaps the most significant role of the nuclear lamina is that of 
maintaining the integrity of the NE (6), it also determines the size and shape of the 
nucleus (27). Another function of the lamina is to attach to the annular subunits of the 
nuclear pore complexes controlling their arrangement in the NE (19). Lamins have been 
found not only lining the inner nuclear membrane but also further inside of the nucleus, 
suggesting that they also form a structural framework deeper inside the nucleus (19). The 
close proximity of the nuclear lamina to chromatin has led some to propose that it also 
has a role in anchoring and organizing chromatin (2). It has also been hypothesized that 
lamins play a role in DNA replication, specifically the elongation phase (2).
Lamins A & C
A-type lamins, which include lamin A and lamin C, are encoded by a gene 
(LMNA) located on chromosome 1q21.2. Alternative splicing of this gene produces 
either lamin A or lamin C. These proteins are identical for the first 566 amino acids and 
diverge at their carboxyl termini. Pre-lamin A has 98 distinctive carboxyl terminal amino 
acids, of which the last 18 amino acids are removed to form lamin A, while lamin C has 6 
carboxyl terminal amino acids (22). The last four amino acids of lamin A form a CaaX 
(cysteine-aliphatic-aliphaticany amino acid) sequence. Post-translational modifications 
involving farnesylation and proteolytic cleavage are necessary for lamin A’s insertion 
into the inner nuclear membrane (INM). Lamin C does not contain this CaaX sequence, 
therefore it’s insertion into the INM is dependent upon lamin A. An additional structural 
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aspect in which lamins A and C differ is that lamin C contains six amino acids in the 
middle of exon 10 that lamin A does not (30). 
An investigation by Lin et al., determined the structure of the LMNA gene. This 
gene contains 12 exons spread over approximately 24 kilobases. All 11 introns contain 
the nucleotides GT at their 5’ end, and a pyrimidine-rich region followed by AG at the 3’ 
end. Exon 1 codes for the globular amino-terminal head in the first part of the central 
helical rod domain of both lamins A and C. The remainder of the central  helical rod 
domain for both proteins is encoded by exons 2-6. Exons 7-9 code for the carboxyl-
terminal tail domains, that are common among lamins A and C. The splice site for 
generating either lamin A or C is contained within exon 10. Finally, located in exons 11-
12 are lamin A specific sequences coding for the CaaX box. Exons 11 and 12 also 
comprise the 3’ region of lamin A (32). 
 As previously stated, alternative splicing of the LMNA gene in exon 10 gives rise 
to either pre-lamin A or lamin C mRNA. Amino acid 566 is the last 3’ amino acid 
common to the two proteins. Following amino acid 566 are six additional lamin C 
specific amino acids and a TGA termination codon. Located 77 nucleotides 3’ to the 
TGA termination codon is the polyadenylation signal of lamin C. Pre-lamin A is formed 
by the splicing of 743 nucleotides to the 3’ end of nucleotide 566. The termination codon, 
TAA, is located in exon 12 and 952 nucleotides 3’ to this codon is the polyadenylation 
sequence. Pre-lamin A is polyadenlyated 16 nucleotides 3’ to this sequence (32). 
 Lamins A and C are expressed in most terminally differentiated mammalian cells; 
however, in early mammalian embryos and some undifferentiated cells these proteins are 
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absent. Lamins A and C seem to be expressed in equal amounts or not at all in cells; 
therefore, it is unlikely that alternative splicing favors one over the other (32). 
 It has been hypothesized that lamins A and C function in DNA replication and 
transcription. Moir et al showed that disruption of lamin organization blocks the 
elongation phase of DNA replication (38). Furthermore, Spann et al showed that 
disruption of the lamin organization inhibits RNA polymerase II, which ultimately affects 
transcription (16).
Sometimes diseases resulting from mutations in two or more different genes will 
exhibit similar phenotypes; however, rarely do mutations in just one gene result in 
numerous diseases. In recent years, mutations in one gene, lamin A/C, have been found to 
be associated with several seemingly different and unrelated diseases. Diseases caused by 
mutations in lamin A/C are collectively referred to as laminopathies.  The laminopathies 
can be grouped according to the tissue they affect; striated muscle, adipose and bone 
tissues, peripheral nervous tissue and finally an ailment affecting many tissues and 
causing premature aging (45). 
Laminopathies associated with muscular diseases differ in the specific muscle 
tissue affected, either cardiac or skeletal, and also in onset of the condition. Emery-
Dreifuss muscular dystrophy (EDMD) is distinguished by three clusters of ailments: (a) 
early onset contractures at the neck, ankles and elbows, (b) slow and progressive muscle 
wasting, and (c) cardiac conduction defects. Heart problems, beginning with conduction 
defects, do not usually develop until the second decade. Most EDMD patients develop 
cardiac arrthymias, leading to complete heart block and sudden heart failure.   Muscles in 
the shoulders, upper arm and lower leg exhibit the most severe muscle wasting. The joint 
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contractures are the least understood of the symptoms; it is yet to be determined if they 
are a result of muscle shortening or due to shortening of the tendons (2). 
There are two forms of EDMD, the X-linked and the autosomal dominant 
varieties (AD-EDMD). X-linked EDMD is inherited by a mutation in the emerin gene 
which encodes the nuclear membrane protein emerin (2). Emerin is closely related in 
sequence and structure to the other nuclear envelope proteins, lamins A and C which 
arise from the lamin A/C gene (24). A missense mutation in the lamin A/C gene produces 
AD-EDMD (4). The similarity in phenotypes of the two forms of EDMD suggests a close 
functional relationship between the emerin protein and the lamin A/C proteins. Cao et. al 
showed emerin and lamin A/C are indeed linked (8). Furthermore, lamin A/C has been 
found to direct normal emerin localization at the inner nuclear membrane (43). 
Another disease associated with lamin A/C that affects striated muscle tissue is 
Limb Girdle Muscular Dystrophy type 1B (LGMD1B). LGMD1B has been mapped to 
the same chromosomal locus as AD-EDMD and is inherited as a slowly progressive 
autosomal dominant trait. Symptoms include cardiac conduction disturbances, dilated 
cardiomyopathy and the absence of early contractures (43). Three mutations in the lamin 
A/C gene of affected patients that were not present in unaffected control subjects have 
been identified. There are genetic and non-genetic factors which cause differences in 
phenotypes between AD-EDMD and LGMD1B; however, both disorders are the result of 
a disease-causing mutation in the same gene (8). 
Dilated cardiomyopathy (DCM), characterized by enlargement of the heart’s 
chambers and impaired systolic contraction, is a principal cause of congestive heart 
failure (10). DCM can be genetically transmitted and DCM associated with conduction -
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system disease was mapped to the same region of chromosome 1 as AD-EDMD (29). As 
stated previously, heart conduction defects are one of the symptoms of AD-EDMD (2). 
Given the location of lamin A/C on chromosome 1 and the cardiovascular phenotype 
associated with AD-EDMD, it was hypothesized that a mutation in the lamin A/C gene 
caused DCM. Evidence for this hypothesis was established by Fatkin et. al (12). 
Dunnigan-type familial partial lipodystrophy (FPLD) is a rare autosomal-
dominant disease characterized by loss of adipose tissue. Individuals with FPLD have 
normal fat distribution at birth, but during puberty they lose subcutaneous fat from the
extremities, trunk and gluteal region. While excess fat may be deposited on the face, neck 
and back, there are normal stores of inter-muscular, intra-abdominal, intrathoracic and 
bone marrow fat. Additionally, those with FPLD often exhibit insulin resistance with 
hyperinsulinemia and develop diabetes later in life (17; 7).
The FPLD gene was mapped to the same region of chromosome 1 as lamin A/C 
by several groups (26; 28; 2). Using previous knowledge of the role of mutations in lamin 
A/C associated with autosomal-dominant Emery-Dreifuss muscular dystrophy (AD-
EDMD), researchers hypothesized that mutations in lamin A/C may also be responsible 
for the progressive degeneration of adipocytes occurring in FPLD. Subsequently, the 
LMNA R482Q mutation was identified as underlying the site-specific adipocyte 
degeneration observed in FPLD (8). 
An additional adipose tissue affecting disease, Mandibuloacral Dysplasia (MAD), 
is caused by a mutation in lamin A/C. MAD is a rare autosomal recessive disorder with 
onset during midchildhood. This disease is characterized by mandibular and clavicular 
hypoplasia, delayed closure of the cranial suture, joint contractures, hyperpigmentation, 
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lipodystrophy and several characteristics of the metabolic syndrome (15). Novelli et. al. 
studied the adipose tissue distribution among individuals diagnosed with MAD and 
accordingly described two separate patterns. Type A pattern restricted fat loss to the 
extremities while type B pattern showed a more generalized subcutaneous fat loss (37). 
The metabolic symptoms and partial lipodystrophy characteristics of MAD are 
similar to FPLD. The similarities in the two conditions prompted investigators to screen 
MAD patients for mutations in the lamin A/C gene. It was found that a missense 
mutation, R527H, resulted in MAD (37). 
The C1908T Polymorphism
A genetic variation in lamin A/C has been reported to be associated with obesity-
related anthropometric and biochemical traits in aboriginal Canadians and Inuit (21; 8), 
higher fasting triglyceride, lower HDL-cholesterol concentrations and the metabolic 
syndrome in an Amish population (2) and reduced subcutaneous abdominal adipocyte 
size in Pima Indians (44). Specifically, the mutation is a common single nucleotide 
polymorphism (SNP) in exon 10 of LMNA. This silent CT substitution occurs at 
nucleotide 1908 and affects the third base within codon 566, which is also the last codon 
shared between lamins A and C before alternative splicing produces one of these proteins 
(21). 
 Hegele et. al. investigated the C1908T polymorphism among Oji-Cree aboriginal 
Canadians and also among the Canadian Inuit. It was determined that in the Oji-Cree 
population the frequencies for the C and T alleles were 23% and 77%, respectively, and 
the genotype frequencies were as follows, 5% CC homozygous, 36% heterozygous  and 
59% TT homozygotes. Comparisons made between C-allele carriers and the TT 
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homozygotes showed that the TT homozygous had significantly higher indices of obesity 
(21). Among the Inuit population, frequencies for the C and T alleles were 52% and 48% 
respectively, and the genotype frequencies were as follows, 23% CC homozygous, 58% 
heterozygous  and 19% TT homozygous. During this study, comparisons were made 
between T allele carriers and CC homozygotes, revealing that those with the T allele had 
increased indices of obesity (8).
Among another population, the Old Order Amish, allele and genotype frequencies 
were similar to those in the Inuit population. The frequencies for the C and T alleles were 
65% and 35% respectively, and the genotype frequencies were as follows, 42% CC 
homozygous, 45% heterozygous and 12% TT homozygous. Researchers also made 
comparisons between T allele carriers and CC homozygotes, finding that the T allele was 
associated with increased occurrence of the metabolic syndrome, increased fasting 
triglycerides and decreased HDL levels (2).
Weyer et al. reported that allele frequencies among the Pima Indians were 55% 
for the C allele and 45% for the T allele. The genotype frequencies among this population 
were 29% CC homozygous, 51% heterozygous and 20% TT homozygous. Weyer et al. 
made comparisons between all three genotype groups and found that the T allele was 
associated with decreased subcutaneous abdominal adipocyte size and also increased 
insulin sensitivity (44). 
Exercise training has been shown to have a positive effect on all of the above 
mentioned factors which are a result of the C1908T SNP and independently contribute to 
type 2 diabetes and cardiovascular disease. The interactive effect of exercise training and 
this polymorphism has not yet been investigated. 
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Summary
This review has discussed the prevalence of and risks associated with the 
metabolic syndrome and its components, in addition to their heritability. This review has 
also addressed the effects of aerobic exercise training on the metabolic syndrome and the 
heritability of exercise training. A genetic variation in the Lamin A/C gene has been 
reported in the literature to contribute to the prevalence of the metabolic syndrome and its 
components which are risk factors for type 2 diabetes and cardiovascular disease. It 
appears that those individuals with the C allele of the Lamin A/C gene are at a greater 
risk for developing the metabolic syndrome and its components. Also, those with the C 
allele may receive a greater benefit from aerobic exercise training concerning the 
metabolic syndrome and its components. These benefits may include a decrease in 
percent body fat, improved lipoprotein-lipid profile and increased insulin sensitivity.
52
References - Literature Review
1. American Heart Association. 2002 Heart and Stroke Statistical Update.  Dallas, 
Texas, American Heart Association. 2001. 
2. Anderson JL, Khan M, David WS, Mahdavi Z, Nuttall FQ, Krech E, West SG, 
Vance JM, Pericak-Vance MA and Nance MA. Confirmation of linkage of 
hereditary partial lipodystrophy to chromosome 1q21-22. Am J Med Genet 82: 161-
165, 1999.
3. Austin MA, Edwards KL, McNeely MJ, Chandler WL, Leonetti DL, Talmud 
PJ, Humphries SE and Fujimoto WY. Heritability of multivariate factors of the 
metabolic syndrome in nondiabetic Japanese americans. Diabetes 53: 1166-1169, 
2004.
4. Bonne G, Di Barletta MR, Varnous S, Becane HM, Hammouda EH, Merlini L, 
Muntoni F, Greenberg CR, Gary F, Urtizberea JA, Duboc D, Fardeau M, 
Toniolo D and Schwartz K. Mutations in the gene encoding lamin A/C cause 
autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 21: 285-288, 
1999.
5. Bouchard C, Leon AS, Rao DC, Skinner JS, Wilmore JH and Gagnon J. The 
HERITAGE family study. Aims, design, and measurement protocol. Med Sci Sports 
Exerc 27: 721-729, 1995.
6. Burke B and Stewart CL. Life at the edge: the nuclear envelope and human 
disease. Nat Rev Mol Cell Biol 3: 575-585, 2002.
7. Burn J and Baraitser M. Partial Lipoatrophy with Insulin Resistant Diabetes and 
Hyperlipemia (Dunnigan Syndrome). Journal of Medical Genetics 23: 128-130, 
1986.
8. Cao H and Hegele RA. Nuclear lamin A/C R482Q mutation in Canadian kindreds 
with Dunnigan-type familial partial lipodystrophy. Human Molecular Genetics 9: 
109-112, 2000.
53
9. Chagnon YC, Rice T, Perusse L, Borecki IB, Ho-Kim MA, Lacaille M, Pare C, 
Bouchard L, Gagnon J, Leon AS, Skinner JS, Wilmore JH, Rao DC and 
Bouchard C. Genomic scan for genes affecting body composition before and after 
training in Caucasians from HERITAGE. J Appl Physiol 90; 1777-1787, 2001.
10. Dec GW and Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med  331: 
1564-1575, 1994.
11. Durstine JL, Grandjean PW, Cox CA and Thompson PD. Lipids, lipoproteins, 
and exercise. J Cardiopulm Rehabil 22: 385-398, 2002.
12. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, Atherton 
J, Vidaillet HJ, Spudich S, De Girolami U, Seidman JG, Seidman CE, Muntoni 
F, Muehle G, Johnson W and McDonough B. Missense mutations in the rod 
domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-
system disease. New England Journal of Medicine 341: 1715-1724, 1999.
13. Feitosa MF, Rice T, Rankinen T, Almasy L, Leon AS, Skinner JS, Wilmore 
JH, Bouchard C and Rao DC. Common Genetic and Environmental Effects on 
Lipid Phenotypes: The HERITAGE Family Study. Hum Hered 59: 34-40, 2005.
14. Foster DW. Insulin resistance--a secret killer? N Engl J Med 320: 733-734, 1989.
15. Freidenberg GR, Cutler DL, Jones MC, Hall B, Mier RJ, Culler F, Jones KL, 
Lozzio C and Kaufmann S. Severe insulin resistance and diabetes mellitus in 
mandibuloacral dysplasia. Am J Dis Child 146: 93-99, 1992.
16. Garcia CA. A clinical review of Charcot-Marie-Tooth. Ann N Y Acad Sci 883: 69-
76, 1999.
17. Garg A, Peshock RM and Fleckenstein JL. Adipose tissue distribution pattern in 
patients with familial partial lipodystrophy (Dunnigan variety). Journal of Clinical 
Endocrinology and Metabolism 84: 170-174, 1999.
18. Genest J, Jr., Marcil M, Denis M and Yu L. High density lipoproteins in health 
and in disease. J Investig Med 47: 31-42, 1999.
54
19. Goldberg MW and Allen TD. The nuclear pore complex and lamina: three-
dimensional structures and interactions determined by field emission in-lens 
scanning electron microscopy. J Mol Biol 257: 848-865, 1996.
20. Halverstadt A, Phares DA, Ferrell RE, Wilund KR, Goldberg AP and Hagberg 
JM. High- density lipoprotein-cholesterol, its subfractions, and responses to exercise 
training are dependent on endothelial lipase genotype. Metabolism 52: 1505-1511, 
2003.
21. Hegele RA, Cao HN, Harris SB, Zinman B, Hanley AJ and Anderson CM. 
Genetic variation in LMNA modulates plasma leptin and indices of obesity in 
aboriginal Canadians. Physiological Genomics 3: 39-44, 2000.
22. Holtz D, Tanaka RA, Hartwig J and McKeon F. The CaaX motif of lamin A 
functions in conjunction with the nuclear localization signal to target assembly to 
the nuclear envelope. Cell 59: 969-977, 1989.
23. Hong YL, Rice T, Gagnon J, Despres JP, Nadeau A, Perusse L, Bouchard C, 
Leon AS, Skinner JS, Wilmore JH and Rao DC. Familial clustering of insulin 
and abdominal visceral fat: The HERITAGE family study. Journal of Clinical 
Endocrinology and Metabolism 83: 4239-4245, 1998.
24. Hozak P, Sasseville AM, Raymond Y and Cook PR. Lamin proteins form an 
internal nucleoskeleton as well as a peripheral lamina in human cells. J Cell Sci 108 
( Pt 2): 635-644, 1995.
25. Hsu FC, Lenchik L, Nicklas BJ, Lohman K, Register TC, Mychaleckyj J, 
Langefeld CD, Freedman BI, Bowden DW and Carr JJ. Heritability of body 
composition measured by DXA in the diabetes heart study. Obes Res 13: 312-319, 
2005.
26. Hsueh WC, St Jean PL, Mitchell BD, Pollin TI, Knowler WC, Ehm MG, Bell 
CJ, Sakul H, Wagner MJ, Burns DK and Shuldiner AR. Genome-wide and fine-
mapping linkage studies of type 2 diabetes and glucose traits in the Old Order 
Amish - Evidence for a new diabetes locus on chromosome 14q11 and confirmation 
of a locus on chromosome 1q21-q24. Diabetes 52: 550-557, 2003.
27. Hutchison CJ. Lamins: building blocks or regulators of gene expression? Nat Rev 
Mol Cell Biol 3: 848-858, 2002.
55
28. Jackson SN, Pinkney J, Bargiotta A, Veal CD, Howlett TA, McNally PG, 
Corral R, Johnson A and Trembath RC. A defect in the regional deposition of 
adipose tissue (partial lipodystrophy) is encoded by a gene at chromosome 1q. Am J 
Hum Genet 63: 534-540, 1998.
29. Kass S, MacRae C, Graber HL, Sparks EA, McNamara D, Boudoulas H, 
Basson CT, Baker PB, III, Cody RJ, Fishman MC. A gene defect that causes 
conduction system disease and dilated cardiomyopathy maps to chromosome 1p1-
1q1. Nat Genet 7: 546-551, 1994.
30. Kitten GT and Nigg EA. The CaaX motif is required for isoprenylation, carboxyl 
methylation, and nuclear membrane association of lamin B2. J Cell Biol 113: 13-23, 
1991.
31. Lakka TA, Rankinen T, Weisnagel SJ, Chagnon YC, Rice T, Leon AS, Skinner 
JS, Wilmore JH, Rao DC and Bouchard C. A quantitative trait locus on 7q31 for 
the changes in plasma insulin in response to exercise training - The HERITAGE 
Family Study. Diabetes 52: 1583-1587, 2003.
32. Lin F and Worman H.J. Structural Organization of the Human Gene Encoding 
Nuclear Lamin-A and Nuclear Lamin-C. J Biol Chem 22; 16321-16326, 1993.
33. Loos RJF, Katzmarzyk PT, Rao DC, Rice T, Leon AS, Skinner JS, Wilmore 
JH, Rankinen T and Bouchard C. Genome-wide linkage scan for the metabolic 
syndrome in the HERITAGE Family Study. Journal of Clinical Endocrinology and 
Metabolism 88: 5935-5943, 2003.
34. McKenzie JA, Weiss EP, Ghiu IA, Kulaputana O, Phares DA, Ferrell RE and 
Hagberg JM. Influence of the interleukin-6 -174 G/C gene polymorphism on 
exercise training-induced changes in glucose tolerance indexes. J Appl Physiol 97: 
1338-1342, 2004.
35. Moir RD, Spann TP, Herrmann H and Goldman RD. Disruption of nuclear 
lamin organization blocks the elongation phase of DNA replication. Journal of Cell 
Biology 149: 1179-1191, 2000.
36. Musliner TA and Krauss RM. Lipoprotein subspecies and risk of coronary 
disease. Clin Chem 34: B78-B83, 1988.
56
37. Novelli G, Muchir A, Sangiuolo F, Helbling-Leclerc A, D'Apice MR, Massart 
C, Capon F, Sbraccia P, Federici M, Lauro R, Tudisco C, Pallotta R, Scarano 
G, Dallapiccola B, Merlini L and Bonne G. Mandibuloacral dysplasia is caused 
by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet 71: 426-431, 2002.
38. Poirier P and Despres JP. Exercise in weight management of obesity. Cardiol 
Clin 19: 459-470, 2001.
39. Pollin TI, Hsueh WC, Steinle NI, Snitker S, Shuldiner AR and Mitchell BD. A 
genome-wide scan of serum lipid levels in the Old Order Amish. Atherosclerosis
173: 89-96, 2004.
40. Rice T, Despres JP, Perusse L, Hong Y, Province MA, Bergeron J, Gagnon J, 
Leon AS, Skinner JS, Wilmore JH, Bouchard C and Rao DC. Familial 
aggregation of blood lipid response to exercise training in the health, risk factors, 
exercise training, and genetics (HERITAGE) Family Study. Circulation 105: 1904-
1908, 2002.
41. Ryan AS. Insulin resistance with aging: effects of diet and exercise. Sports Med 30: 
327-346, 2000.
42. Shoulders CC, Jones EL and Naoumova RP. Genetics of familial combined 
hyperlipidemia and risk of coronary heart disease. Hum Mol Genet 13 Spec No 1: 
R149-R160, 2004.
43. Sullivan T, Escalante-Alcalde D, Bhatt H, Anver M, Bhat N, Nagashima K, 
Stewart CL and Burke B. Loss of A-type lamin expression compromises nuclear 
envelope integrity leading to muscular dystrophy. J Cell Biol 147: 913-920, 1999.
44. Weyer C, Wolford JK, Hanson RL, Foley JE, Tataranni PA, Bogardus C and 
Pratley RE. Subcutaneous abdominal adipocyte size, a predictor of type 2 diabetes, 
is linked to chromosome 1q21-q23 and is associated with a common polymorphism 
in LMNA in Pima Indians. Molecular Genetics and Metabolism 72: 231-238, 2001.
45. Worman HJ and Courvalin JC. How do mutations in lamins A and C cause 
disease? J Clin Invest 113: 349-351, 2004.
57
APPENDIX C: FORMS 
Informed consent
APO E genotype and HDL Changes with Exercise Training
58
APPENDIX C
INFORMED CONSENT
CONSENT TO ACT AS A SUBJECT IN AN EXPERIMENTAL STUDY
Project Title: APO E genotype and HDL Changes with Exercise Training
I state that I am over 18 years of age and wish to participate in a program of research 
being conducted by Dr. James Hagberg in the Department of Kinesiology, University 
of Maryland.
The purpose of this study is to determine the role that genetics may play in 
determining how my blood cholesterol levels change with exercise training.
I already completed a telephone interview that determined that I am not physically 
active, am 50 - 75 years of age, not a diabetic or have controlled diabetes, not taking 
cholesterol-lowering medications, have normal blood pressure or high blood pressure 
controlled on medications not affecting my cholesterol levels, have no evidence of lung 
disease, have an appropriate body weight for my height, and have no other medical 
problems that would keep me from exercising vigorously. Furthermore, if I am a woman, I 
must be postmenopausal, defined as no menstrual cycles for at least the last 2 years. I 
understand that if I am a woman and change my hormone replacement therapy regimen 
during the study, my participation in the study will be terminated. I also understand that if 
I have a prior history of ulcers or bleeding disorders, I will be excluded from one test that 
is part of this study. I also understand that I must have somewhat abnormal levels of 
cholesterol to enter the study.
I understand that I will complete one orientation and two screening visits.  The 
orientation session will present all aspects of the study and my written informed 
consent will be provided after all of my questions have been answered.  For my first 
Screening visit, I will report to the laboratory in the morning after an overnight fast 
and a blood sample will be drawn for blood chemistries and blood cholesterol levels.  
I understand that I may be excluded from the study if this initial blood sample shows 
elevated levels of glucose in my blood. I understand that a part of this blood sample 
will be used to obtain my DNA.  A blood sample will also be drawn 2 hours after I 
drink a sugar solution.  I understand that a total of 3 tablespoons of blood will be
drawn during this visit.  I understand that I will be excluded from the study at this 
point if I have low cholesterol levels, high triglyceride levels, a low red blood cell 
count, evidence of kidney or liver disease, or evidence of diabetes.  I understand that 
if I remain qualified to this point, on my second Screening Visit I will undergo a 
treadmill exercise test to determine if I have heart disease.  A physical examination 
will precede the exercise test.  I will then complete a test on an exercise treadmill 
where the treadmill speed and grade will increase every 3 minutes until I cannot 
continue or symptoms of heart disease develop.  Blood pressure, heart rate, and ECG 
will be recorded before, during, and after the test.  I understand that I will be excluded 
from the study at this point if I have evidence of heart disease.
I understand that if I meet all of these requirements to enter the study, I will 
undergo 6-8 weeks of instruction in the principles of an American Heart Association low-
fat diet and must follow this diet for the remainder of this study.  After this I will undergo 
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Baseline Testing that includes the following tests that will be completed in 5 
Page One of Five Initials ______________
testing sessions.  I will have my blood drawn on 2 or 3 occasions from a vein in my arm 
in the morning after an overnight fast to measure my cholesterol levels and to assess my 
immune system.  I understand that a maximum of 2 tablespoons of blood will be drawn 
during these visits.  I understand that I will also undergo a second exercise test on a 
treadmill to measure my cardiovascular fitness. This test will start at
70% of the highest heart rate achieved on my first exercise test and the treadmill grade will 
increase by 2% every 2 minutes.  Blood pressure, heart rate, and ECG will be monitored 
before, during, and after the test.  The test will be stopped when I can no longer continue.  
During this test I will have a noseclip on my nose and I will breathe through a mouthpiece 
so that the air that I breathe out can be analyzed.  I also understand that my dietary habits 
will be measured by having me record for 7 days all of the food items that I eat.  I 
understand that on another morning after an overnight fast I will have blood samples 
drawn before and for 3 hours after I drink a glucose solution to assess my risk of 
developing diabetes; I will also have additional blood drawn prior to this test that will be 
frozen for future studies that relate directly to the goals of the present study.  I understand 
that 5 tablespoons of blood will be drawn during this visit.  I understand that on another 
occasion after an overnight fast, I will have blood samples drawn from a line (catheter) in 
my arm before and for 4 hours after drinking approximately 1 – 2 cups of a high-fat liquid 
meal. The high-fat meal is made of heavy whipping cream with small amounts of 
chocolate, sugar, and powdered milk and tastes similar to a rich chocolate shake. I 
understand that 10 tablespoons of blood will be drawn during this test and will be used to 
measure how my body absorbs and uses fat from a meal and how my blood clotting, and 
substances that affect hunger are affected by a fat meal. Before and after I drink the high-
fat meal, I understand that I will breath through a mouthpiece while my nose is closed-off 
with a nose clip and the air that I breath out will be collected and used to determine how 
much fat I use for energy while sitting at rest. I understand that these tests will be done at 
the University of Maryland College Park. 
I understand that in the morning after an overnight fast I will have blood samples 
drawn to assess my cholesterol levels and blood clotting system.  I will then have a substance 
that temporarily stops blood from clotting injected into my arm vein.  Blood samples are 
drawn 10 minutes later for measurement of chemicals that affect blood cholesterol levels.  I 
understand that if I have a prior history of ulcers or bleeding disorders I will not undergo this 
test.  I understand that I will remain in the laboratory for 2 - 3 hours after this test with 
pressure on the site where blood samples were drawn to make sure that all bleeding is 
stopped.  I understand that 4 tablespoons of blood will be drawn during this visit.  I 
understand that how much fat and muscle I have will be measured using x-rays while I lie 
quietly on a table for 15 to 30 minutes.  I understand that the amount of fat I have around my 
waist will be measured with a CAT scan while I lie quietly on a table.  I also understand that 
these last 3 tests will be done at the VA Medical Center in Baltimore.
I understand that during this Baseline Testing a total of 21 tablespoons of blood will 
be drawn, which is about two-thirds of the amount of blood given when donating blood.
Page Two of Five Initials _________________
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I understand that after completing this testing, for 6 months I will complete 3 
exercise sessions each week supervised by study personnel.  I understand that I will be 
instructed on appropriate warmup and stretching exercises to perform prior to each exercise 
training session.  I will be taught to measure my heart rate and to use heart rate monitors to 
control how hard I am exercising.  The first training sessions will consist of 20 minutes of 
light exercise.  The amount of exercise and how hard I exercise will increase gradually until 
I am completing 40 minutes of moderate intensity exercise every session.  Exercise modes 
include walk/jogging, stairstepping, and cycle, cross-country ski, and rowing ergometry.  I 
will be asked to add a 45-60 minute walk to my exercise program on weekends after the 
first 10 weeks of the exercise program.  I understand that some of the supervised exercise 
sessions may be done outside of the exercise facility, but still under the direct supervision 
of study personnel.  I understand that if I lose more weight than expected from the exercise, 
I will be counseled by a dietitian against restricting how much food I eat.  I will also be 
asked to complete food records during the exercise training program and if major dietary 
changes have occurred, I will also be counseled by a dietitian to resume my original dietary 
habits.
I understand that after completing 6 months of exercise training, I will have 
everything reevaluated that was measured before I began the exercise program.  I 
understand that during this testing a maximum of 21 tablespoons of blood will be drawn, 
which is about two-thirds of the amount of blood given when donating blood.
I understand that if I qualify for this study that my DNA will be isolated from my 
blood and analyzed at a number of sites for differences in DNA that may affect how my 
cholesterol levels change with exercise training.  I understand that some of my DNA will 
also be frozen for future studies.  However, these studies can only analyze my DNA at 
sites that might affect how my cholesterol levels, glucose and insulin levels, bone density, 
body composition, immunology (disease-fighting), and cardiovascular blood clotting 
systems change with exercise training.
All information collected in this study is confidential, and my name will not be 
identified at any time.  I understand that my DNA (genetic material) will be sent to 
laboratories at the University of Pittsburgh and the University of Maryland at Baltimore 
School of Medicine that are part of this study.  I understand, however, that my DNA 
samples sent to the University of Pittsburgh and the University of Maryland at Baltimore 
will be identified only by a numeric code.  I understand that my coded blood samples are 
also sent to the University of Florida and to a company in North Carolina to measure 
compounds in my blood that relate to blood cholesterol levels and cardiovascular disease 
risk.  I understand that only investigators at the University of Maryland College Park will 
know whose name is associated with each coded number.  I further understand that the list 
of names and codes will be retained at the University of Maryland for up to 25 years.
I understand the following risks are associated with my participation in this study. (1) The 
risk of maximal exercise testing is approximately 1 nonfatal event in 10,000 tests and 1 fatal 
cardiac event in 70,000 tests.  Risks will be minimized by having the test administered by a 
physician and personnel trained in such tests and emergency procedures.  I will be screened 
with a resting ECG and a physical examination prior to 
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this test.  An emergency cart with the necessary drugs and a cardiac defibrillator will be 
present at all testing sessions.  (2) There is minimal risk of bruising and infection associated 
with blood drawing.  These risks will be minimized by using sterile techniques and by 
having experienced personnel draw all blood samples. (3) The risk of the body composition 
testing is the exposure to X-rays.  The amount of x-ray exposure for this test is the same as 
that occurring during 30 minutes of any activity outside in the sun. (4) The risk associated 
with the test requiring the injection into an arm vein of a substance that temporarily stops 
blood clotting is bleeding.  This risk will be minimized by excluding persons with bleeding 
disorders, peptic ulcers, or other blood disorders from the study.  The risk is further 
minimized by placing a pressure bandage on the intravenous access site after the blood 
sampling and observing the subject for 2-3 hours after the injection. (5) The risk associated 
with the CAT scan to measure abdominal fat is the exposure to x-rays.  The x-ray exposure 
is less than the maximum radiation dose individuals are permitted to be exposed to each year 
in their occupation.  (6) The risks associated with the blood clotting and immune system 
studies are those related to blood drawing as listed above. (7) The risks associated with the 
oral glucose tolerance test and the high-fat meal test are those associated with blood 
drawing, the possibility of having low blood sugar levels at the end of the test, and the 
possibility of having an upset stomach, primarily a stomach ache, after drinking the glucose 
and/or high-fat meals.  The risk of low blood sugar levels at the end of the test will be 
minimized by providing you with a drink and small snack. (8) The risk of exercise training 
is the possibility of a heart attack or other cardiovascular event.  A large physical activity 
center reported that 1 nonfatal cardiovascular event occurred in 1.7 million walk/jogging 
miles. These risks will be minimized because I will undergo a cardiovascular evaluation 
before beginning exercise training.  Exercise sessions will be supervised by experienced 
personnel trained in emergency procedures. An emergency cart with the necessary drugs and 
a cardiac defibrillator will be present at all supervised exercise training sessions. Two study 
personnel will supervise the outside exercise sessions done at the University of Maryland, 
College Park though no emergency equipment will be directly available during these 
sessions.  (9) There are no risks associated with the genetic testing because no results of 
these tests will be given to the participants.  This has to be the case because the genetic 
results are not from clinically-approved laboratories.
I understand that this study is not designed to help me personally, but may help the 
investigators to determine who exercise might benefit the most.  I understand that I will be 
provided with my study results and they can be sent to my physician if I request this in 
writing.  I understand that these results are not to be used for clinical diagnostic purposes 
and that I will not receive the results of my genetic testing.  I understand that I am free to 
ask questions or to withdraw from participation at any time without penalty.  I understand 
that I will be paid $50 for completing Baseline Testing after the dietary stabilization period.  
I also understand that I will be paid another $50 for completing 3 months of exercise 
training and another $100, for a total of $200, for completing 6 months of exercise training 
and all final testing, if I complete at least 90% of my exercise training and testing sessions.  
I understand that if my participation in the study has to be terminated because I change my 
hormone replacement therapy regimen, I will 
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only be paid for the portion of the study that I have already completed, that is, which of the 
stages above that I have completed.
In the event of a physical injury resulting from participation in this study, I 
understand that immediate medical attention is available at the Washington Adventist 
Hospital or the Baltimore VA Medical Center.  However, I understand that the University 
of Maryland does not provide any medical or hospitalization coverage for participants in 
this research study nor will the University of Maryland provide any compensation for any 
injury sustained as a result of participation in this research study except as required by 
law.
Principal Investigator: James Hagberg, PhD.  Department of Kinesiology.  HLHP 
Building.  University of Maryland, College Park, MD 20742-2611, telephone 301-405-
2487.
__________________ __________________
Subject’s signature Date
__________________ __________________
Witness Date
__________________ __________________
Investigator Date
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